- Siren Biotechnology and Catalent Inc. have formed a strategic partnership to develop and manufacture Siren’s AAV immuno-gene therapies.
- Catalent will provide process development and cGMP manufacturing of Siren’s AAV vector-based therapeutic candidates for clinical trials.
Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., recently acquired by Novo Holdings, have announced a strategic partnership. The collaboration is set to bolster the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.
Under the agreement, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology’s adeno-associated viral (AAV) vector-based therapeutic candidates. These will be used in clinical trials. Furthermore, Catalent will support process optimisation at its process and clinical development centre in Baltimore, MD.
Dr. Nicole Paulk, CEO, Founder, and President of Siren Biotechnology, expressed her anticipation for the partnership. She said, “We look forward to working with Catalent, a leading CDMO with premier capabilities in AAV vector development and manufacturing, on the development of our AAV Immuno-Gene Therapies. This partnership demonstrates our commitment to a robust manufacturing process that will move our therapeutic programs into the clinic as quickly as possible.”
David McErlane, Group President of Biologics at Catalent, echoed this sentiment. He stated, “Catalent is committed to partnering early in the development process with innovative companies like Siren. We are excited to work together to pioneer a pathway for the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to patients with cancer.”
Overview of outsourcing trends 
